








Advancing science in dermatology

Project*	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
PIPELINE Q4-2021							
Tralokinumab LP0162	An IL-13 anti-inflammatory monoclonal antibody under development for atopic dermatitis.		Finalized phase	Finalized phase	Finalized phase	Finalized phase	Current phase
Delgocitinib LP0133	A topical pan-JAK inhibitor under development for chronic hand eczema.		Finalized phase	Finalized phase	Finalized phase	Current phase	
Anti IgE⁺B-cell LP0201	A monoclonal antibody under development for atopic dermatitis and allergic asthma.		Finalized phase	Finalized phase	Current phase		
Anti IL-22R LP0145	An anti-inflammatory monoclonal antibody under development for atopic dermatitis.		Finalized phase	Finalized phase	Current phase		
H4R antagonist LP0190	A systemic anti-pruritic and anti-inflammatory H4 receptor antagonist under development for atopic dermatitis.		Finalized phase	Finalized phase	Current phase		
IL-17A PPI LP0200	An IL-17 small-molecule modulator under development for psoriasis.		Finalized phase	Current phase			

*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.

 Finalized phase  Current phase

